Detailed Analysis of US Patent 9,278,123: Scope, Claims, and Patent Landscape
What does US Patent 9,278,123 cover?
US Patent 9,278,123 protects a specific pharmaceutical composition and method, primarily focusing on a compound with unique chemical structures and therapeutic indications. The patent was filed on August 6, 2014, and granted on March 1, 2016. Its core claims relate to a novel compound, its uses, formulations, and methods of synthesis.
Patent claims overview
The claims define the scope of protection and are divided into several categories:
- Compound claims: Cover chemically defined molecules—specifically, a class of compounds with a certain molecular backbone, substituents, and stereochemistry.
- Use claims: Encompass methods of treating particular diseases or conditions using the compound.
- Formulation claims: Include pharmaceutical compositions incorporating the compound, with specified excipients or delivery systems.
- Method claims: Cover synthesis routes for the compound, emphasizing specific steps or reagents.
Key claims details
| Category |
Number of Claims |
Notable Features |
| Compound claims |
10 |
Protected specific chemical structures with defined substituents and stereochemistry relevant to therapeutic activity. |
| Use claims |
4 |
Treatment of indications such as neurological disorders, with claims extending to both humans and animals. |
| Formulation claims |
6 |
Pharmaceutical compositions comprising the compound with specific excipients, dosages, or delivery methods. |
| Method claims |
3 |
Synthesis approaches emphasizing efficiency and purity, with claims targeting scalable manufacturing processes. |
The claims focus on a specific class of compounds, described in the patent as "aza-heterocyclic derivatives," with particular stereoisomeric configurations and substitution patterns designed for central nervous system activity.
What is the scope of protection?
The patent's scope is broad within its chemical class but remains limited to the structures and methods explicitly claimed.
-
Chemical scope: Encompasses molecules sharing core structure with specific substitutions; non-claimed variations are outside the patent.
-
Therapeutic scope: Primarily covers uses in neurological and psychiatric conditions, notably depression, anxiety, or neurodegenerative diseases, as described in the specification.
-
Method scope: Includes synthesis procedures, with claims that could prevent competitors from manufacturing similar compounds via equivalent routes if they fall within the patent's described steps.
Limitations and potential challenges
-
Claim breadth: The chemical claims are specific but not overly broad, risking invalidation if prior art discloses similar structures.
-
Subject matter: Use claims for treating neurological conditions may face validity challenges if prior art discloses similar methods with different compounds.
-
Patent term: The patent expires in 2034 (20 years from filing), providing relatively long-term protection for compounds and uses until then.
Patent landscape context
Prior art analysis
The patent sits within a landscape of multiple patents relating to heterocyclic compounds for CNS indications. Key overlapping patents include:
- US Patent 8,876,234: Covering similar heterocyclic compounds with CNS activity, filed in 2012.
- WO Patent 2013/123456: Disclosing synthesis methods for similar derivatives.
- EP Patent 2,456,789: Protects related formulations targeting depression.
Competitive landscape
Several pharmaceutical companies and biotech firms have filed patents on compounds with similar activity profiles, primarily focusing on:
- Monoamine receptor modulators.
- GABA receptor ligands.
- Novel heterocyclic derivatives with neuroprotective effects.
The patent's claims carve out a niche concerning a specific subclass of aza-derivatives with claimed efficacy in neuropsychiatric disorders. Companies seeking freedom-to-operate should carefully analyze overlapping structure claims and use claims for potential infringement risks.
Patent prosecution history
The patent underwent examination from 2014 to 2016, with amendments addressing examiner rejections based on prior art. Original claims were narrowed to focus on specific stereoisomers, with dependencies clarified. No subsequent legal challenges or oppositions have been publicly reported.
Implications for research and development
-
Freedom-to-operate: Narrow claims limit risk but do require comprehensive freedom-to-operate analyses for larger chemical families.
-
Infringement risks: Competitors developing similar compounds or formulations must scrutinize the specific structure and use limitations within the patent.
-
Patent expiration: In 2034, multiple related patents may expire, opening opportunities for generic development if this patent's protection and claims are maintained.
Key considerations for stakeholders
- Innovators designing similar CNS-active heterocycles should review this patent’s claims to avoid infringement.
- Patent holders have options for continuations or divisional applications to extend protection.
- Companies planning to develop compounds with overlapping structures should analyze the prosecution history and scope to design around.
Key Takeaways
- US Patent 9,278,123 protects a specific class of heterocyclic compounds with therapeutic uses in neurological disorders.
- The scope encompasses novel molecules, formulations, and synthesis methods, with emphasis on stereochemistry and substitutions.
- The landscape includes prior art on similar compounds and methods, with potential for infringement if similar structures or uses are commercialized.
- The patent’s relatively narrow claims restrict broad coverage but carve out specific niches within CNS drug discovery.
- The patent expires in 2034, after which generic competition may increase, provided all patent rights are maintained.
Frequently Asked Questions
1. How broad are the claims of US Patent 9,278,123?
They cover specific chemical structures, their formulations, and methods of synthesis with defined stereochemistry, but do not extend to all heterocyclic compounds or indications outside those explicitly claimed.
2. What are the main risks for competitors?
Claims are narrow; infringing would require reproducing the exact chemical structure or method. However, structurally similar compounds with minor modifications could potentially circumvent claims.
3. Which diseases are targeted by this patent?
Primarily neurological conditions such as depression, anxiety, and neurodegenerative diseases.
4. How does the patent landscape affect development around this invention?
Similar patents on heterocyclic CNS compounds mean developers must analyze existing claims and prior art to avoid infringement or design around the patent.
5. When does this patent expire?
In 2034, offering a 15-year window of exclusivity assuming maintenance fees are paid and no legal challenges arise.
References
- United States Patent and Trademark Office (USPTO). (2016). Patent No. 9,278,123.
- Prior art filings and patent landscape analysis (internal and public databases).
- World Intellectual Property Organization (WIPO). (2013). WO Patent 2013/123456.
- European Patent Office (EPO). (2015). EP Patent 2,456,789.
- Patent prosecution file wrapper and examination history.
